PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis

Human Reproduction Update - Tập 29 Số 6 - Trang 741-772 - 2023
Mercedes Millán-de-Meer1, Manuel Luque‐Ramírez2,3,1, Lía Nattero‐Chávez2,3, Héctor F. Escobar‐Morreale2,3,1
1Universidad de Alcalá, Madrid, Spain
2Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid, Spain
3Grupo de Diabetes, Obesidad y Reproducción Humana, Universidad de Alcalá & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) & Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) , Madrid, Spain

Tóm tắt

Abstract BACKGROUND Current knowledge about the consequences of PCOS during the late reproductive years and after menopause is limited. OBJECTIVE AND RATIONALE We performed a systematic review and meta-analysis of data on the pathophysiology, clinical manifestations, diagnosis, prognosis, and treatment of women ≥45 years of age—peri- or postmenopausal—with PCOS. SEARCH METHODS Studies published up to 15 April 2023, identified by Entrez-PubMed, EMBASE, and Scopus online facilities, were considered. We included cross-sectional or prospective studies that reported data from peri- or postmenopausal patients with PCOS and control women with a mean age ≥45 years. Three independent researchers performed data extraction. Meta-analyses of quantitative data used random-effects models because of the heterogeneity derived from differences in study design and criteria used to define PCOS, among other confounding factors. Sensitivity analyses restricted the meta-analyses to population-based studies, to studies including only patients diagnosed using the most widely accepted definitions of PCOS, only menopausal women or only women not submitted to ovarian surgery, and studies in which patients and controls presented with similar indexes of weight excess. Quality of evidence was assessed using the GRADE system. OUTCOMES The initial search identified 1400 articles, and another six were included from the reference lists of included articles; 476 duplicates were deleted. We excluded 868 articles for different reasons, leaving 37 valid studies for the qualitative synthesis, of which 28 studies—published in 41 articles—were considered for the quantitative synthesis and meta-analyses. Another nine studies were included only in the qualitative analyses. Compared with controls, peri- and postmenopausal patients with PCOS presented increased circulating total testosterone (standardized mean difference, SMD 0.78 (0.35, 1.22)), free androgen index (SMD 1.29 (0.89, 1.68)), and androstenedione (SMD 0.58 (0.23, 0.94)), whereas their sex hormone-binding globulin was reduced (SMD −0.60 (−0.76, −0.44)). Women with PCOS showed increased BMI (SMD 0.57 (0.32, 0.75)), waist circumference (SMD 0.64 (0.42, 0.86)), and waist-to-hip ratio (SMD 0.38 (0.14, 0.61)) together with increased homeostasis model assessment of insulin resistance (SMD 0.56 (0.27, 0.84)), fasting insulin (SMD 0.61 (0.38, 0.83)), fasting glucose (SMD 0.48 (0.29, 0.68)), and odds ratios (OR, 95% CI) for diabetes (OR 3.01 (1.91, 4.73)) compared to controls. Women with PCOS versus controls showed decreased HDL concentrations (SMD −0.32 (−0.46, −0.19)) and increased triglycerides (SMD 0.31 (0.16, 0.46)), even though total cholesterol and LDL concentrations, as well as the OR for dyslipidaemia, were similar to those of controls. The OR for having hypertension was increased in women with PCOS compared with controls (OR 1.79 (1.36, 2.36)). Albeit myocardial infarction (OR 2.51 (1.08, 5.81)) and stroke (OR 1.75 (1.03, 2.99)) were more prevalent in women with PCOS than controls, the ORs for cardiovascular disease as a whole, coronary artery disease as a whole, breast cancer and age at menopause, were similar in patients and controls. When restricting meta-analysis to studies in which women with PCOS and controls had a similar mean BMI, the only difference that retained statistical significance was a decrease in HDL-cholesterol concentration in the former and, in the two studies in which postmenopausal women with PCOS and controls had similar BMI, patients presented with increased serum androgen concentrations, suggesting that hyperandrogenism persists after menopause, regardless of obesity. WIDER IMPLICATIONS Hyperandrogenism appeared to persist during the late-reproductive years and after menopause in women with PCOS. Most cardiometabolic comorbidities were driven by the frequent coexistence of weight excess and PCOS, highlighting the importance of targeting obesity in this population. However, the significant heterogeneity among included studies, and the overall low quality of the evidence gathered here, precludes reaching definite conclusions on the issue. Hence, guidelines derived from adequately powered prospective studies are definitely needed for appropriate management of these women.

Từ khóa


Tài liệu tham khảo

Alpanes, 2012, Management of postmenopausal virilization, J Clin Endocrinol Metab, 97, 2584, 10.1210/jc.2012-1683

Alsamarai, 2009, Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age, J Clin Endocrinol Metab, 94, 4961, 10.1210/jc.2009-0839

Amiri, 2020, Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression, Reprod Biol Endocrinol, 18, 23, 10.1186/s12958-020-00576-1

Anagnostis, 2021, Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies, Endocrine, 74, 245, 10.1007/s12020-021-02801-2

Anderson, 1997, Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa, Cancer, 79, 494, 10.1002/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.0.CO;2-Z

Armeni, 2013, Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype, J Hypertens, 31, 1998, 10.1097/HJH.0b013e3283630362

Asuncion, 2000, A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain, J Clin Endocrinol Metab, 85, 2434

Azziz, 2006, Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline, J Clin Endocrinol Metab, 91, 4237, 10.1210/jc.2006-0178

Balen, 2001, Polycystic ovary syndrome and cancer, Hum Reprod Update, 7, 522, 10.1093/humupd/7.6.522

Barry, 2014, Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis, Hum Reprod Update, 20, 748, 10.1093/humupd/dmu012

Birdsall, 1996, Polycystic ovaries in pre and post-menopausal women, Clin Endocrinol (Oxf), 44, 269, 10.1046/j.1365-2265.1996.676498.x

Chan, 2013, Premature aging of cardiovascular/platelet function in polycystic ovarian syndrome, Am J Med, 126, 640.e1, 10.1016/j.amjmed.2012.12.015

Cheang, 2008, Risk of cardiovascular events in mothers of women with polycystic ovary syndrome, Endocr Pract, 14, 1084, 10.4158/EP.14.9.1084

Cibula, 2000, Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome, Hum Reprod, 15, 785, 10.1093/humrep/15.4.785

Dahlgren, 1994, Hemostatic and metabolic variables in women with polycystic ovary syndrome, Fertil Steril, 61, 455, 10.1016/S0015-0282(16)56575-3

Dahlgren, 1992, Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones, Fertil Steril, 57, 505, 10.1016/S0015-0282(16)54892-4

Deniz, 2021, The association between knee osteoarthritis and polycystic ovary syndrome in postmenopausal women: preliminary results, Eur Rev Med Pharmacol Sci, 25, 4895

Diamanti-Kandarakis, 2012, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications, Endocr Rev, 33, 981, 10.1210/er.2011-1034

Ding, 2018, Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: a population-based cohort study in Taiwan, Medicine (Baltimore), 97, e12608, 10.1097/MD.0000000000012608

Dokras, 2022, Heart health in polycystic ovary syndrome: time to act on the data, Fertil Steril, 117, 885, 10.1016/j.fertnstert.2022.03.014

Echiburu, 2016, Metabolic profile in women with polycystic ovary syndrome across adult life, Metabolism, 65, 776, 10.1016/j.metabol.2016.01.006

Elhassan, 2018, Causes, patterns, and severity of androgen excess in 1205 consecutively recruited women, J Clin Endocrinol Metab, 103, 1214, 10.1210/jc.2017-02426

Elting, 2001, Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population, Hum Reprod, 16, 556, 10.1093/humrep/16.3.556

Escobar-Morreale, 2007, Abdominal adiposity and the polycystic ovary syndrome, Trends Endocrinol Metab, 18, 266, 10.1016/j.tem.2007.07.003

Escobar-Morreale, 2008, A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs, J Clin Endocrinol Metab, 93, 527, 10.1210/jc.2007-2053

Escobar-Morreale, 2018, Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment, Nat Rev Endocrinol, 14, 270, 10.1038/nrendo.2018.24

Falcetta, 2021, Effect of aging on clinical features and metabolic complications of women with polycystic ovary syndrome, J Endocrinol Invest, 44, 2725, 10.1007/s40618-021-01594-5

Forslund, 2023, No difference in morbidity between perimenopausal women with PCOS with and without previous wedge resection, Eur J Obstet Gynecol Reprod Biol, 285, 74, 10.1016/j.ejogrb.2023.04.008

Forslund, 2022, Health-related quality of life in perimenopausal women with PCOS, Clin Exp Obstet Gynecol, 49, 52, 10.31083/j.ceog4902052

Forslund, 2019, Higher menopausal age but no differences in parity in women with polycystic ovary syndrome compared with controls, Acta Obstet Gynecol Scand, 98, 320, 10.1111/aogs.13489

Forslund, 2020, Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution, Hum Reprod Open, 2020, hoz042, 10.1093/hropen/hoz042

Forslund, 2021, Reproductive hormones and anthropometry: a follow-up of PCOS and controls from perimenopause to older than 80 years, J Clin Endocrinol Metab, 106, 421, 10.1210/clinem/dgaa840

Forslund, 2022, Morbidity and mortality in PCOS: a prospective follow-up up to a mean age above 80 years, Eur J Obstet Gynecol Reprod Biol, 271, 195, 10.1016/j.ejogrb.2022.02.020

Gabrielli, 2012, Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare, Reprod Biol Endocrinol, 10, 96, 10.1186/1477-7827-10-96

Gabrielli, 2015, Proposed criteria for the identification of polycystic ovary syndrome following menopause: an ancillary study of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), Maturitas, 81, 398, 10.1016/j.maturitas.2015.04.013

Gammon, 1991, Polycystic ovaries and the risk of breast cancer, Am J Epidemiol, 134, 818, 10.1093/oxfordjournals.aje.a116156

Guoqing, 2016, Cerebral white matter lesions and silent cerebral infarcts in postmenopausal women with polycystic ovary syndrome, Gynecol Endocrinol, 32, 655, 10.3109/09513590.2016.1149812

Helvaci, 2022, The impact of ageing and menopause in women with polycystic ovary syndrome, Clin Endocrinol (Oxf), 97, 371, 10.1111/cen.14558

Hendriks, 2007, Why does ovarian surgery in PCOS help? Insight into the endocrine implications of ovarian surgery for ovulation induction in polycystic ovary syndrome, Hum Reprod Update, 13, 249, 10.1093/humupd/dml058

Hernández-Mijares, 2013, Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome, Eur J Clin Invest, 43, 549, 10.1111/eci.12080

Iatrakis, 2006, Women younger than 50 years with endometrial cancer, Eur J Gynaecol Oncol, 27, 399

Karjula, 2017, Psychological distress is more prevalent in fertile age and premenopausal women with PCOS symptoms: 15-year follow-up, J Clin Endocrinol Metab, 102, 1861, 10.1210/jc.2016-3863

Karjula, 2020, Population-based data at ages 31 and 46 show decreased HRQoL and life satisfaction in women with PCOS symptoms, J Clin Endocrinol Metab, 105, 1814, 10.1210/clinem/dgz256

Kim, 2018, Androgens, irregular menses, and risk of diabetes and coronary artery calcification in the Diabetes Prevention Program, J Clin Endocrinol Metab, 103, 486, 10.1210/jc.2017-01829

Kim, 2016, Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case-control study, Cancer Causes Control, 27, 403, 10.1007/s10552-016-0716-7

Krentz, 2009, Reduced serum ghrelin in a putative postmenopausal polycystic ovary syndrome phenotype, Fertil Steril, 92, 1753, 10.1016/j.fertnstert.2009.05.039

Krentz, 2007, Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease, Menopause, 14, 284, 10.1097/GME.0b013e31802cc7ab

Krentz, 2012, Adipocytokine profiles in a putative novel postmenopausal polycystic ovary syndrome (PCOS) phenotype parallel those in premenopausal PCOS: the Rancho Bernardo Study, Metabolism, 61, 1238, 10.1016/j.metabol.2012.02.001

Kujanpää, 2022, Women with polycystic ovary syndrome are burdened with multimorbidity and medication use independent of body mass index at late fertile age: a population-based cohort study, Acta Obstet Gynecol Scand, 101, 728, 10.1111/aogs.14382

Legro, 2003, Polycystic ovary syndrome and cardiovascular disease: a premature association?, Endocr Rev, 24, 302, 10.1210/er.2003-0004

Li, 2016, Common diseases as determinants of menopausal age, Hum Reprod, 31, 2856, 10.1093/humrep/dew264

Livadas, 2020, Insulin resistance, androgens, and lipids are gradually improved in an age-dependent manner in lean women with polycystic ovary syndrome: insights from a large Caucasian cohort, Hormones (Athens), 19, 531, 10.1007/s42000-020-00211-z

Luque-Ramirez, 2015, Referral bias in female functional hyperandrogenism and polycystic ovary syndrome, Eur J Endocrinol, 173, 603, 10.1530/EJE-15-0646

Luque-Ramirez, 2007, Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syndrome, J Clin Endocrinol Metab, 92, 2141, 10.1210/jc.2007-0190

Luque-Ramirez, 2014, Office blood pressure, ambulatory blood pressure monitoring, and echocardiographic abnormalities in women with polycystic ovary syndrome: role of obesity and androgen excess, Hypertension, 63, 624, 10.1161/HYPERTENSIONAHA.113.02468

Margolin, 2005, Polycystic ovary syndrome in post-menopausal women–marker of the metabolic syndrome, Maturitas, 50, 331, 10.1016/j.maturitas.2004.09.005

Markopoulos, 2015, Hyperandrogenism after menopause, Eur J Endocrinol, 172, R79, 10.1530/EJE-14-0468

Markopoulos, 2011, Hyperandrogenism in women with polycystic ovary syndrome persists after menopause, J Clin Endocrinol Metab, 96, 623, 10.1210/jc.2010-0130

Markopoulos, 2013, Study of carbohydrate metabolism indices and adipocytokine profile and their relationship with androgens in polycystic ovary syndrome after menopause, Eur J Endocrinol, 168, 83, 10.1530/EJE-12-0550

Matsuda, 1999, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp, Diabetes Care, 22, 1462, 10.2337/diacare.22.9.1462

McGuinness, 2021, Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments, Res Synth Methods, 12, 55, 10.1002/jrsm.1411

McKinlay, 1992, The normal menopause transition, Maturitas, 14, 103, 10.1016/0378-5122(92)90003-M

Merz, 2016, Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome, J Womens Health (Larchmt), 25, 875, 10.1089/jwh.2015.5441

Meun, 2018, High androgens in postmenopausal women and the risk for atherosclerosis and cardiovascular disease: the Rotterdam Study, J Clin Endocrinol Metab, 103, 1622, 10.1210/jc.2017-02421

Meun, 2020, The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome, Clin Endocrinol (Oxf), 92, 150, 10.1111/cen.14117

Minooee, 2018, Prediction of age at menopause in women with polycystic ovary syndrome, Climacteric, 21, 29, 10.1080/13697137.2017.1392501

Mulhall, 2018, Variation in symptoms of depression and anxiety in midlife women by menopausal status, Maturitas, 108, 7, 10.1016/j.maturitas.2017.11.005

Naderpoor, 2016, Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis, Hum Reprod Update, 22, 408, 10.1093/humupd/dmv063

Ollila, 2019, Self-reported polycystic ovary syndrome is associated with hypertension: a Northern Finland Birth Cohort 1966 Study, J Clin Endocrinol Metab, 104, 1221, 10.1210/jc.2018-00570

Ollila, 2016, Weight gain and dyslipidemia in early adulthood associate with polycystic ovary syndrome: prospective cohort study, J Clin Endocrinol Metab, 101, 739, 10.1210/jc.2015-3543

Ollila, 2017, Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus – a prospective, population-based cohort study, Hum Reprod, 32, 423, 10.1093/humrep/dew329

Ortiz-Flores, 2019, Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: fasting plasma glucose or oral glucose tolerance test?, Metabolism, 93, 86, 10.1016/j.metabol.2019.01.015

Page, 2021, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 372, n71, 10.1136/bmj.n71

Parazzini, 1997, Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa, Cancer, 80, 1360, 10.1002/(SICI)1097-0142(19971001)80:7<1360::AID-CNCR28>3.3.CO;2-X

Persson, 2023, Hyperandrogenic symptoms are a persistent suffering in midlife women with PCOS; a prospective cohort study in Sweden, Biomedicines, 11, 96, 10.3390/biomedicines11010096

Pinola, 2015, Androgen profile through life in women with polycystic ovary syndrome: a Nordic Multicenter Collaboration Study, J Clin Endocrinol Metab, 100, 3400, 10.1210/jc.2015-2123

Polonen, 2022, Polycystic ovary syndrome and leukocyte telomere length: cross-sectional and longitudinal changes, Eur J Endocrinol, 187, 651, 10.1530/EJE-22-0462

Polotsky, 2012, Relative contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women, J Clin Endocrinol Metab, 97, E868, 10.1210/jc.2011-3357

Polotsky, 2014, Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition, J Clin Endocrinol Metab, 99, 2120, 10.1210/jc.2013-4170

Puurunen, 2009, Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 94, 1973, 10.1210/jc.2008-2583

Puurunen, 2011, Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS, J Clin Endocrinol Metab, 96, 1827, 10.1210/jc.2011-0039

Ramezani Tehrani, 2020, Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis, Gynecol Endocrinol, 36, 12, 10.1080/09513590.2019.1650337

Schmidt, 2011, Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls, J Clin Endocrinol Metab, 96, 2178, 10.1210/jc.2010-2959

Schmidt, 2012, Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome – a long-term follow-up study, Clin Endocrinol (Oxf), 77, 207, 10.1111/j.1365-2265.2012.04378.x

Schmidt, 2017, High androgen levels protect against hypothyroidism, Acta Obstet Gynecol Scand, 96, 39, 10.1111/aogs.13054

Schmidt, 2011, Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study, J Clin Endocrinol Metab, 96, 3794, 10.1210/jc.2011-1677

Snyder, 2014, Complement protein C3 and coronary artery calcium in middle-aged women with polycystic ovary syndrome and controls, Gynecol Endocrinol, 30, 511, 10.3109/09513590.2014.895985

Sterne, 2005, Publication Bias in Meta-Analysis – Prevention, Assessment and Adjustments

Talbott, 1998, Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study, J Clin Epidemiol, 51, 415, 10.1016/S0895-4356(98)00010-9

Talbott, 2000, Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women, Arterioscler Thromb Vasc Biol, 20, 2414, 10.1161/01.ATV.20.11.2414

Talbott, 2008, Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women?, Vasc Health Risk Manag, 4, 453, 10.2147/VHRM.S1452

Talbott, 2004, The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome, J Clin Endocrinol Metab, 89, 6061, 10.1210/jc.2003-032110

Talbott, 2004, Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome, J Clin Endocrinol Metab, 89, 5454, 10.1210/jc.2003-032237

Teede, 2018, Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome, Hum Reprod, 33, 1602, 10.1093/humrep/dey256

The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), Hum Reprod, 19, 41, 10.1093/humrep/deh098

Wan, 2014, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range, BMC Med Res Methodol, 14, 135, 10.1186/1471-2288-14-135

Wekker, 2020, Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis, Hum Reprod Update, 26, 942, 10.1093/humupd/dmaa029

Welt, 2013, Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause, J Clin Endocrinol Metab, 98, 4629, 10.1210/jc.2013-2375

Wickenheisser, 2006, Human ovarian theca cells in culture, Trends Endocrinol Metab, 17, 65, 10.1016/j.tem.2006.01.003

Wild, 2010, Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society, J Clin Endocrinol Metab, 95, 2038, 10.1210/jc.2009-2724

Wild, 2011, Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis, Fertil Steril, 95, 1073, 10.1016/j.fertnstert.2010.12.027

Wild, 2000, Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study, Hum Fertil (Camb), 3, 101, 10.1080/1464727002000198781

Winters, 2000, Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome, Fertil Steril, 73, 724, 10.1016/S0015-0282(99)00641-X

Yildiz, 2012, Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria, Hum Reprod, 27, 3067, 10.1093/humrep/des232

Yin, 2018, Association between polycystic ovary syndrome and hot flash presentation during the midlife period, Menopause, 25, 691, 10.1097/GME.0000000000001055

Zawadzki, 1992, Polycystic Ovary Syndrome

Zhu, 2019, Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis, Fertil Steril, 111, 168, 10.1016/j.fertnstert.2018.09.013

Zucchetto, 2009, Hormone-related factors and gynecological conditions in relation to endometrial cancer risk, Eur J Cancer Prev, 18, 316, 10.1097/CEJ.0b013e328329d830

Thông tin
Thông tin xuất bản

Human Reproduction Update

Tập 29 Số 6

741-772

Thông tin tác giả